Funding information: Alberta Health Services Health Outcomes Improvement Fund; Women and Children's Health Research Institute; GDCB was supported by an Alberta Health Services Chair in Obesity Research

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Summary

Introduction

Cardiovascular disease (CVD) originates in childhood and risk is exacerbated in obesity. Mechanisms of the etiologic link between early adiposity and CVD-risk remain unclear. Postprandial or non-fasting dyslipidemia is characterized by elevated plasma triglycerides (TG) and intestinal-apolipoprotein(apo)B48-remnants following a high-fat meal and is a known CVD-risk factor in adults. The aim of this study was to determine (a) whether the fasting concentration of apoB48-remnants can predict impaired non-fasting apoB48-lipoprotein metabolism (fat intolerance) and (b) the relationship of these biomarkers with cardiometabolic risk factors in youth with or without obesity.

Methods

We assessed fasting and non-fasting lipids in youth without obesity (n = 22, 10 males, 12 females) and youth with obesity (n = 13, 5 males, 8 females) with a mean BMI Z-score of 0.19 ± 0.70 and 2.25 ± 0.31 (P = .04), respectively.

Results

Fasting and non-fasting apoB48-remnants were elevated in youth with obesity compared to youth without obesity (apoB48: 18.04 ± 1.96 vs 8.09 ± 0.59, P < .0001, and apoB48_AUC: 173.0 ± 20.86 vs 61.99 ± 3.44, P < .001). Furthermore, fasting plasma apoB48-remnants were positively correlated with the non-fasting response in apoB48_AUC (r = 0.84, P < .0001) as well as other cardiometabolic risk factors including HOMA-IR (r = 0.61, P < .001) and leptin (r = 0.56, P < .0001).

Conclusion

Fasting apoB48-remnants are elevated in youth with obesity and predict apoB48 postprandial dyslipidemia. ApoB48-remnants are associated with the extent of fat intolerance and appear to be potential biomarker of CVD-risk in youth.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

Supporting Information

REFERENCES

1Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011; 365(20): 1876-1885.
10.1056/NEJMoa1010112
CAS PubMed Web of Science® Google Scholar
2Twig G, Zucker I, Afek A, et al. Adolescent obesity and early-onset type 2 diabetes. Diabetes Care. 2020; 43: 1487-1495.
10.2337/dc19-1988
PubMed Web of Science® Google Scholar
3Higgins V, Adeli K. Pediatric metabolic syndrome: pathophysiology and laboratory assessment. EJIFCC. 2017; 28(1): 25-42.
CAS PubMed Google Scholar
4Kavey RE, Daniels SR, Lauer RM, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003; 107(11): 1562-1566.
10.1161/01.CIR.0000061521.15730.6E
PubMed Web of Science® Google Scholar
5 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128(Suppl 5): S213-S256.
10.1542/peds.2009-2107C
PubMed Google Scholar
6Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008; 122(1): 198-208.
10.1542/peds.2008-1349
PubMed Web of Science® Google Scholar
7Wang Y, Pendlebury C, Dodd MM, et al. Elevated remnant lipoproteins may increase subclinical CVD risk in pre-pubertal children with obesity: a case-control study. Pediatr Obes. 2013; 8(5): 376-384.
10.1111/j.2047-6310.2012.00116.x
CAS PubMed Web of Science® Google Scholar
8Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61(4): 427-436.
10.1016/j.jacc.2012.08.1026
CAS PubMed Web of Science® Google Scholar
9Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014; 141(3): 358-367.
10.1016/j.pharmthera.2013.11.008
CAS PubMed Web of Science® Google Scholar
10Alipour A, Valdivielso P, Elte JW, et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur J Clin Invest. 2012; 42(7): 702-708.
10.1111/j.1365-2362.2011.02635.x
CAS PubMed Web of Science® Google Scholar
11Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 2002; 13(5): 461-470.
10.1097/00041433-200210000-00001
CAS PubMed Web of Science® Google Scholar
12Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. Jama. 2019; 321(4): 364-373.
10.1001/jama.2018.20045
CAS PubMed Web of Science® Google Scholar
13Smith D, Watts GF, Dane-Stewart C, Mamo JC. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest. 1999; 29(3): 204-209.
10.1046/j.1365-2362.1999.00431.x
CAS PubMed Web of Science® Google Scholar
14Mamo JC, Watts GF, Barrett PH, Smith D, James AP, Pal S. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol Endocrinol Metab. 2001; 281(3): E626-E632.
10.1152/ajpendo.2001.281.3.E626
CAS PubMed Web of Science® Google Scholar
15Wilke MS, Maximova K, Henderson M, et al. Adiposity in children and CVD risk: ApoB48 has a stronger association with central fat than classic lipid markers. J Clin Endocrinol Metab. 2016; 101(7): 2915-2922.
10.1210/jc.2016-1171
CAS PubMed Web of Science® Google Scholar
16Williams JW, Huang LH, Randolph GJ. Cytokine circuits in cardiovascular disease. Immunity. 2019; 50(4): 941-954.
10.1016/j.immuni.2019.03.007
CAS PubMed Web of Science® Google Scholar
17Qin B, Qiu W, Avramoglu RK, Adeli K. Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes. 2007; 56(2): 450-461.
10.2337/db06-0518
CAS PubMed Web of Science® Google Scholar
18Hein GJ, Baker C, Hsieh J, Farr S, Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes. 2013; 62(2): 373-381.
10.2337/db12-0202
CAS PubMed Web of Science® Google Scholar
19Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000; 8(314): 1-27.
Google Scholar
20Reinehr T, de Sousa G, Roth CL. Fasting glucagon-like peptide-1 and its relation to insulin in obese children before and after weight loss. J Pediatr Gastroenterol Nutr. 2007; 44(5): 608-612.
10.1097/MPG.0b013e3180406a24
CAS PubMed Web of Science® Google Scholar
21Vine DF, Wang Y, Jetha MM, Ball GD, Proctor SD. Impaired ApoB-lipoprotein and triglyceride metabolism in obese adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017; 102(3): 970-982.
PubMed Web of Science® Google Scholar
22Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem. 2002; 48(2): 278-283.
10.1093/clinchem/48.2.278
CAS PubMed Web of Science® Google Scholar
23Hounnou G, Destrieux C, Desme J, Bertrand P, Velut S. Anatomical study of the length of the human intestine. Surg Radiol Anat. 2002; 24(5): 290-294.
10.1007/s00276-002-0057-y
CAS PubMed Web of Science® Google Scholar
24Verdam FJ, Greve JW, Roosta S, et al. Small intestinal alterations in severely obese hyperglycemic subjects. J Clin Endocrinol Metab. 2011; 96(2): E379-E383.
10.1210/jc.2010-1333
CAS PubMed Web of Science® Google Scholar
25Altmann GG, Leblond CP. Factors influencing villus size in the small intestine of adult rats as revealed by transposition of intestinal segments. Am J Anat. 1970; 127(1): 15-36.
10.1002/aja.1001270104
CAS PubMed Web of Science® Google Scholar
26James AP, Watts GF, Barrett PH, et al. Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism. 2003; 52(2): 136-141.
10.1053/meta.2003.50032
CAS PubMed Web of Science® Google Scholar
27Ooi TC, Krysa JA, Chaker S, et al. The effect of PCSK9 loss-of-function variants on the postprandial lipid and ApoB-lipoprotein response. J Clin Endocrinol Metab. 2017; 102(9): 3452-3460.
10.1210/jc.2017-00684
PubMed Web of Science® Google Scholar
28Freese EC, Gist NH, Cureton KJ. Effect of prior exercise on postprandial lipemia: an updated quantitative review. J Appl Physiol (1985). 2014; 116(1): 67-75.
10.1152/japplphysiol.00623.2013
CAS PubMed Web of Science® Google Scholar
29Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol. 2006; 26(6): 1357-1363.
10.1161/01.ATV.0000222015.76038.14
CAS PubMed Web of Science® Google Scholar
30Hsieh J, Hayashi AA, Webb J, Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atheroscler Suppl. 2008; 9(2): 7-13.
10.1016/j.atherosclerosissup.2008.05.011
CAS PubMed Web of Science® Google Scholar
31Mulvihill EE. Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. Current Opinion in Lipidology. 2018; 29(2): 95-103.
10.1097/MOL.0000000000000495
CAS PubMed Web of Science® Google Scholar
32Higgins V, Asgari S, Chan MK, Adeli K. Pediatric reference intervals for calculated LDL cholesterol, non-HDL cholesterol, and remnant cholesterol in the healthy CALIPER cohort. Clin Chim Acta. 2018; 486: 129-134.
10.1016/j.cca.2018.07.028
CAS PubMed Web of Science® Google Scholar
33Vine DF, Glimm DR, Proctor SD. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl. 2008; 9(2): 69-76.
10.1016/j.atherosclerosissup.2008.05.004
CAS PubMed Web of Science® Google Scholar
34Wong AT, Chan DC, Pang J, Watts GF, Barrett PH. Plasma apolipoprotein B-48 transport in obese men: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab. 2014; 99(1): E122-E126.
10.1210/jc.2013-2477
PubMed Web of Science® Google Scholar
35Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atheroscler Suppl. 2008; 9(2): 33-38.
10.1016/j.atherosclerosissup.2008.05.013
CAS PubMed Web of Science® Google Scholar
36Umano GR, Pistone C, Tondina E, et al. Pediatric obesity and the immune system. Front Pediatr. 2019; 7: 487.
10.3389/fped.2019.00487
PubMed Web of Science® Google Scholar
37Mao J, Hu X, Xiao Y, et al. Overnutrition stimulates intestinal epithelium proliferation through beta-catenin signaling in obese mice. Diabetes. 2013; 62(11): 3736-3746.
10.2337/db13-0035
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume16, Issue5

May 2021

e12745

ApoB-lipoprotein remnant dyslipidemia and high-fat meal intolerance is associated with markers of cardiometabolic risk in youth with obesity

Summary

Introduction

Methods

Results

Conclusion

CONFLICT OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

ApoB-lipoprotein remnant dyslipidemia and high-fat meal intolerance is associated with markers of cardiometabolic risk in youth with obesity

Summary

Introduction

Methods

Results

Conclusion

CONFLICT OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Related

Information